Skip to main content
SpringerLink
Log in

Sporadic Medullary Thyroid Cancer

  • Chapter
  • First Online:
Thyroid and Parathyroid Diseases

  • 1138 Accesses

Abstract

Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland. It accounts for approximately 1–2% of thyroid cancers. The production of calcitonin is a characteristic feature of this tumor. Most of the MTCs are sporadic whereas 25% of cases are familial as part of the multiple endocrine neoplasia type 2 (MEN2) syndrome. For sporadic MTCs, there are no germline RET mutations. The most common presentation of sporadic MTC is a solitary thyroid nodule. Systemic symptoms may occur due to hormonal secretion by the tumor. Most sporadic MTCs also secrete carcinoembryonic antigen (CEA). The diagnosis of sporadic MTC is usually made after fine needle aspiration (FNAB) biopsy in a patient who has a solitary thyroid nodule. Patients with sporadic MTC can be cured only by complete resection of the thyroid tumor with bilateral central neck lymph node dissection. For patients with the residual or recurrent disease after primary surgery or for those with distant metastases, the most appropriate treatment is less clear and still debatable.

In this case presentation, we discussed a patient with an MTC, its evaluation, diagnosis, management and the future of the MTC according to the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567.

    Article  Google Scholar 

  2. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984;63:319.

    Article  CAS  Google Scholar 

  3. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77:1556.

    Article  CAS  Google Scholar 

  4. Gagel RF, Hoff AO, Cote GJ. Medullary thyroid carcinoma. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 967.

    Google Scholar 

  5. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139.

    Article  CAS  Google Scholar 

  6. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:475.

    Article  CAS  Google Scholar 

  7. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;31:1960.

    Article  Google Scholar 

  8. Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R, et al. Medullary thyroid microcarcinoma recommendations for treatment—a single-center experience. Surgery. 2007;142:1003.

    Article  Google Scholar 

  9. Machens A, Dralle H. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol. 2016;175:219.

    Article  CAS  Google Scholar 

  10. Kwon H, Kim WG, Sung TY, Jeon MJ, Song DE, Lee YM, et al. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma. J Surg Oncol. 2016;113:152.

    Article  Google Scholar 

  11. Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg. 2007;142:289.

    Article  CAS  Google Scholar 

  12. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53:278.

    Article  CAS  Google Scholar 

  13. Trimboli P, Nasrollah N, Amendola S, Rossi F, Ramacciato G, Romanelli F, et al. Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer? Endocr J. 2012;59:503.

    Article  Google Scholar 

  14. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol. 2005;91:56.

    Article  Google Scholar 

  15. Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist. 2011;16:49.

    Article  Google Scholar 

  16. Toledo SP, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo). 2009;64:699.

    Article  Google Scholar 

  17. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med. 2005;142:926.

    Article  Google Scholar 

  18. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 20 Aug 2012.

  19. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF, GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077.

    Article  CAS  Google Scholar 

  20. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655.

    Article  CAS  Google Scholar 

  21. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590.

    Article  CAS  Google Scholar 

  22. Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med. 2011;13:755.

    Article  CAS  Google Scholar 

  23. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996;81:1619.

    CAS  PubMed  Google Scholar 

  24. American Joint Committee on Cancer (AJCC). In: Edge SB, Byrd DR, Compton CC, et al., editors. Cancer staging manual. 7th ed. New York: Springer; 2010.

    Chapter  Google Scholar 

  25. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 1999;230:697.

    Article  CAS  Google Scholar 

  26. Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1983;57:124.

    Article  CAS  Google Scholar 

  27. Engelbach M, Görges R, Forst T, Pfützner A, Dawood R, Heerdt S, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab. 2000;85:1890.

    CAS  PubMed  Google Scholar 

  28. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990;212:395.

    Article  Google Scholar 

  29. Modigliani E, Cohen R, Campos JM, Franc B, Niccoli-Sire P, Conte-Devolx B, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998;48:265.

    Article  CAS  Google Scholar 

  30. Ho AS, Wang L, Palmer FL, Yu C, Toset A, Patel S, et al. Postoperative nomogram for predicting cancer-specific mortality in medullary thyroid Cancer. Ann Surg Oncol. 2015;22:2700.

    Article  Google Scholar 

  31. Faggiano A, Talbot M, Lacroix L, Bidart JM, Baudin E, Schlumberger M, et al. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol (Oxf). 2002;57:813.

    Article  CAS  Google Scholar 

  32. Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54:657.

    Article  CAS  Google Scholar 

  33. Machens A, Hauptmann S, Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? J Clin Endocrinol Metab. 2008;93:2234.

    Article  CAS  Google Scholar 

  34. Walter MA, Meier C, Radimerski T, Iten F, Kränzlin M, Müller-Brand J, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer. 2010;116:31.

    CAS  PubMed  Google Scholar 

  35. Azar FK, Lee SL, Rosen JE. Medullary thyroid cancer: an update for surgeons. Am Surg. 2015;81:1–8.

    PubMed  Google Scholar 

  36. Skoura E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11:8156. https://doi.org/10.5812/ijem.8156.

    Article  CAS  Google Scholar 

  37. Sugawara M, Ly T, Hershman JM. Medullary thyroid cancer--current treatment strategy, novel therapies, and perspectives for the future. Horm Cancer. 2012;3:218–26. https://doi.org/10.1007/s12672-012-0119-5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Breast and Endocrin Surgery, Kocaeli University, Kocaeli, Turkey

    Nuh Zafer Cantürk, Sertaç Ata Güler & Turgay Şimşek

Authors
  1. Nuh Zafer Cantürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sertaç Ata Güler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Turgay Şimşek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sertaç Ata Güler .

Editor information

Editors and Affiliations

  1. University of Health Sciences (SBÜ) Okmeydanı Training and Research Hospital, Istanbul, Turkey

    Tamer Özülker

  2. University of Health Sciences (SBÜ) Okmeydanı Training and Research Hospital, Istanbul, Turkey

    Mine Adaş

  3. University of Health Sciences (SBÜ) Okmeydanı Training and Research Hospital, Istanbul, Turkey

    Semra Günay

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cantürk, N.Z., Güler, S.A., Şimşek, T. (2019). Sporadic Medullary Thyroid Cancer. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_60

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78476-2_60

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78475-5

  • Online ISBN: 978-3-319-78476-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation